1431 related articles for article (PubMed ID: 9554249)
21. Ovulation inhibition following vaginal administration of pills containing norethindrone and mestranol.
Coutinho EM; Silva AR; Carreira C; Barbosa I
Contraception; 1984 Feb; 29(2):197-202. PubMed ID: 6723313
[TBL] [Abstract][Full Text] [Related]
22. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
van Heusden AM; Fauser BC
Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
[TBL] [Abstract][Full Text] [Related]
23. The effect of contraceptive steroids on hypothalamic-pituitary function.
Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
[TBL] [Abstract][Full Text] [Related]
24. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
[TBL] [Abstract][Full Text] [Related]
25. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
[TBL] [Abstract][Full Text] [Related]
26. Laboratory criteria for menopause in women using oral contraceptives.
Creinin MD
Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
[TBL] [Abstract][Full Text] [Related]
27. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive.
Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR
Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373
[TBL] [Abstract][Full Text] [Related]
28. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
Cameron ST; Thong KJ; Baird DT
Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
30. Reduction of the oral contraceptive estrogen burden by alternate day estrogen administration.
Segre EJ; Henzl MR; Giner J; Scheel C; Bessler S
Contraception; 1975 Aug; 12(2):155-74. PubMed ID: 1139955
[TBL] [Abstract][Full Text] [Related]
31. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
32. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
Scott JZ; Kletzky OA; Brenner PF; Mishell DR
Fertil Steril; 1978 Aug; 30(2):141-5. PubMed ID: 98356
[TBL] [Abstract][Full Text] [Related]
34. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.
Stanczyk FZ; Brenner PF; Mishell DR; Ortiz A; Gentzschein EK; Goebelsmann U
Contraception; 1978 Dec; 18(6):615-33. PubMed ID: 750188
[TBL] [Abstract][Full Text] [Related]
35. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Rosenfeld WE; Doose DR; Walker SA; Nayak RK
Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
[TBL] [Abstract][Full Text] [Related]
36. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
37. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
Landgren BM; Diczfalusy E
Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
[TBL] [Abstract][Full Text] [Related]
38. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
39. Control of fertility with oral medication.
Diddle AW; Watts GF; Gardner WH; Williamson PJ
West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
[TBL] [Abstract][Full Text] [Related]
40. Subdermal norethindrone pellets -- a method for contraception?
Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]